Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma
Top Cited Papers
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 138 (3), 527-533
- https://doi.org/10.1016/j.jid.2017.09.033
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trialThe Lancet Oncology, 2013
- Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trialThe Lancet Oncology, 2013
- Trends in Basal Cell Carcinoma Incidence Rates: A 37-Year Dutch Observational StudyJournal of Investigative Dermatology, 2013
- What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trialBMC Dermatology, 2012
- Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trialsBritish Journal of Dermatology, 2012
- Photodynamic therapy using topical 5‐aminolaevulinic acid vs. surgery for basal cell carcinomaJournal of the European Academy of Dermatology and Venereology, 2012
- A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12‐month follow‐up.Journal of the European Academy of Dermatology and Venereology, 2008
- 5% 5-Fluorouracil Cream for the Treatment of Small Superficial Basal Cell Carcinoma: Efficacy, Tolerability, Cosmetic Outcome, and Patient SatisfactionDermatologic Surgery, 2007
- Skin cancer is among the most costly of all cancers to treat for the Medicare populationJournal of the American Academy of Dermatology, 2003